Crescita Therapeutics (TSX:CTX) Inventories, Other: C$0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSX:CTX Crescita Therapeutics Inc TSX:CTX
20 GF Score
Price C$0.79
! 5 Warning Signs
View Full Analysis

What is Crescita Therapeutics Inventories, Other?

Crescita Therapeutics TSX:CTX 20 Inventories, Other is C$0.00 Mil as of Mar. 2026. GuruFocus rates TSX:CTX with a GF Score™ of 20/100. The stock has 5 warning signs investors should review.

Other inventories including goods for resale, stocks in transit, consignment stocks, etc. Crescita Therapeutics's other inventories for the quarter that ended in Mar. 2026 was C$0.00 Mil.

Crescita Therapeutics's quarterly other inventories stayed the same from Sep. 2025 (C$0.00 Mil) to Dec. 2025 (C$0.00 Mil) and stayed the same from Dec. 2025 (C$0.00 Mil) to Mar. 2026 (C$0.00 Mil).

Crescita Therapeutics's annual other inventories stayed the same from Dec. 2023 (C$0.00 Mil) to Dec. 2024 (C$0.00 Mil) but then increased from Dec. 2024 (C$0.00 Mil) to Dec. 2025 (C$0.00 Mil).

Crescita Therapeutics Inventories, Other Historical Data

* Premium members only.

The historical data trend for Crescita Therapeutics's Inventories, Other can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Crescita Therapeutics Inventories, Other Chart

Crescita Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Inventories, Other
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Crescita Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Inventories, Other Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
TSX:CTX
20GF Score
Crescita Therapeutics Inc TSX:CTX
Inventories, Other is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Crescita Therapeutics Inventories, Other Calculation

Other inventories including goods for resale, stocks in transit, consignment stocks, etc.

Frequently Asked Questions Learn more about Inventories, Other →
What does a Inventories, Other of C$0.00 Mil mean?
Crescita Therapeutics (TSX:CTX) has a Inventories, Other of C$0.00 Mil as of Mar. 2026. Other inventories a company records on its balance sheet, like goods for resale and stocks in transit. View historical data on Crescita Therapeutics and its competitors.
Is Crescita Therapeutics' Inventories, Other too high?
Crescita Therapeutics' current Inventories, Other is C$0.00 Mil. Overall, Crescita Therapeutics has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Crescita Therapeutics' Inventories, Other compare to ZTS?
Crescita Therapeutics' Inventories, Other of C$0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Other for a Drug Manufacturers company?
A good Inventories, Other depends on the Drug Manufacturers industry context. However, Inventories, Other should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Other mean?
A high Inventories, Other can signal that a stock is expensive relative to its fundamentals. Other inventories a company records on its balance sheet, like goods for resale and stocks in transit. View historical data on Crescita Therapeutics and its competitors. Crescita Therapeutics's current Inventories, Other is C$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Crescita Therapeutics stock overvalued right now?
Crescita Therapeutics (TSX:CTX) has a current Inventories, Other of C$0.00 Mil. The current Inventories, Other is C$0.00 Mil. Crescita Therapeutics' overall GF Score™ is 20/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Other calculated?
Inventories, Other is calculated from a company's financial statements. For Crescita Therapeutics (TSX:CTX), the current Inventories, Other is C$0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Crescita Therapeutics Business Description

Address 2805, Place Louis-R-Renaud, Laval, QC, CAN, H7V 0A3
Crescita Therapeutics Inc is a commercial dermatology company with in-house research & development and manufacturing capabilities. The company offers a portfolio of non-prescription skincare products and early to commercial-stage prescription drug products and owns multiple proprietary drug delivery platforms that support the development of patented formulations that can facilitate the delivery of active ingredients into or through the skin. The company has three reportable segments: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services. The firm generates its revenue from Commercial Skincare Product Sales in Canada followed by USA and Rest of the world.
20GF Score

Get the complete analysis for TSX:CTX

Inventories, Other is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$0.79
Price